Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 84 people in total — 23 with a type of hepatitis C called genotype 5, and 61 with a type called genotype 6. Nearly all participants finished the trial (23 out of 23 in the genotype 5 group, and 60 out of 61 in the genotype 6 group). The trial was primarily measuring what is called SVR12 — which means whether the hepatitis C virus was undetectable in a person's blood 12 weeks after they finished treatment. This is a commonly used way of checking whether the virus has cleared. The reported data shows that in the genotype 5 group, 95.7% of participants had undetectable virus levels at the 12-week post-treatment check, compared with 98.4% in the genotype 6 group. For the secondary outcomes, the reported data shows that none of the genotype 5 participants (0.0%) experienced what the trial called "on-treatment virologic failure" — meaning the virus did not rebound to detectable levels while they were still taking the study drug — while 1.6% of the genotype 6 group did. When it came to "relapse" — meaning the virus becoming detectable again after treatment ended — 4.3% of the genotype 5 group were recorded as having relapsed, while 0.0% of the genotype 6 group did. These numbers reflect what was measured and recorded within this particular trial, in these specific groups of participants, under the conditions of the study. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35174470) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your blood tests show you have Hepatitis C virus (HCV) of a specific type — either genotype 5 or genotype 6.
- Your blood tests confirm active Hepatitis C infection, with the virus detected at a certain level in your blood.
- You have either never received any treatment for Hepatitis C before, or you have previously been treated with specific older-type Hepatitis C medications (such as interferon or a drug called sofosbuvir combined with ribavirin) that did not fully work — and that treatment ended at least 2 months before joining the study.
- You either do not have liver scarring (cirrhosis), or if you do, your liver is still functioning reasonably well (known as "compensated" cirrhosis).
Who may not be able to join:
- Women who are currently pregnant, breastfeeding, or planning to become pregnant during the study or within about 30 days after finishing the study medication.
- People who have had a recent problem with drug or alcohol misuse within the past 6 months that might make it difficult to follow the study rules.
- People who test positive for Hepatitis B or HIV at the screening appointment.
- People whose blood tests show they are infected with more than one type (genotype) of Hepatitis C at the same time.
- People who have had a serious or severe allergic reaction to any ingredients in the study medication.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: AbbVie Inc., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.